ArticleRheumatology and therapy2026
Real-World Upadacitinib Persistence and Clinical Outcomes Among Canadian Patients with Inflammatory Arthritis from a Patient Support Program: The UPRAISE Study.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) impact quality of life. Medication persistence is a key determinant of long-term effectiveness in chronic inflammatory diseases. This study evaluated treatment persistence, function, and program satisfaction among Canadian patients with RA, PsA, and axSpA receiving upadacitinib enrolled in the AbbVie Care patient support program (PSP).
methodsData were collected from adults with RA, PsA, or axSpA enrolled in the Canadian PSP between January 2020 and July 2025. Demographic characteristics, first prescription fill rates, medication persistence, Health Assessment Questionnaire Disability Index (HAQ-DI) scores, and patient satisfaction with the PSP (subset of RA patients) were assessed.
resultsA total of 16,075 patients enrolled in the PSP were assessed (RA: N = 11,449; PsA: N = 2751; axSpA N = 1875). Over 90% of all patients filled their first upadacitinib prescription within 7 days. Among patients with RA, medication persistence was 73%, 63%, 56%, and 51% at 12, 24, 36, and 48 months, respectively. In PsA, persistence was 68%, 54%, and 47% at 12, 24, and 36 months, and with axSpA, persistence was 63% and 50% at 12 and 24 months. Patients with RA had a mean reduction from baseline in HAQ-DI of - 0.40 (N = 777; SD: 0.77; P < .001) and most patients (62%) achieved minimal clinically important difference (MCID; improvement ≥ 0.22[RA] or ≥ 0.35[PsA]), with 28% having normative values (HAQ-DI ≤ 0.25). Among patients with PsA, the mean reduction from baseline in HAQ-DI was - 0.65 (N = 153; SD: 0.66; P < 0.001); 73% of patients achieved MCID and 26% had normative values. Among 200 RA patients surveyed, nearly 90% were extremely/very satisfied with the PSP.
conclusionsHigh first prescription fill and long-term persistence rates were observed in patients with RA, PsA, and axSpA enrolled in a single national PSP, along with substantial improvements in physical function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.